Diabetes Mellitus Type 2 is a chronic metabolic disorder that affects approx. 90% of diabetes patients. It is defined as a disease characterized by a deficiency in insulin secretion, resistance to its actions, and an increase in the output of hepatic glucose. Treatment aimed at these metabolic defects can be given in multiple areas, such as pancreas, liver, muscles, adipose tissue, and gastrointestinal tract, providing an adequate glycemic control. Therapy should be chosen according to the patient's needs. Many different types of hypoglycemic drugs are available. Some are sulfonylureas, meglitinides, D-phenylalanine derivatives, biguanides, thiazolidinediones, and alpha-glucosidase inhibitors. In addition, it is usual to find the use of combined treatments to treat hyperglycemia in patients with Diabetes Mellitus Type 2.
Downloads
Download data is not yet available.
References
Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician. 2001;63:1747-56.
Masharani U, Karma JH. Diabetes mellitus & hypoglycemia. In: Tierney LM, McPhee S, Papadakis M, editors. Current medical diagnosis & treatment 2002. 41st ed. United States of America: McGraw Hill; 2002. p. 1212-8.
American Diabetes Association Expert Committee. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183.
Amos AF, McCarty DJ, Zimmer P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14(Suppl 5):1-85.
Haffner SM. Epidemiology of type 2 diabetes: risk factors. Diabetes Care. 1998;21(Suppl 3):C3.
Palumbo PJ. Glycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Mayo Clin Proc. 2001;76:609-18.
United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
White RJ, Campbell RK. Recent developments in the pharmacological reduction of blood glucose in patients with type 2 diabetes. Clin Diabetes. 2001;19:153-9.
Cincinati R, Veliks J. Oral medications. Medical Economics. 2001;64:30-6.
Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UKPDS. Am Heart J. 1999;138:346-52.
Lebovitz HE. Insulin secretagogues: sulfonylureas and meglitinides. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes mellitus: a fundamental and clinical text. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 326-34.
Dornhorst A. Insulinotropic meglitinide analogues. The Lancet. 2001;358:1709.
Drexel AJ, Robertson C. Type 2 diabetes: How new insights, new drugs are changing clinical practice. Geriatrics. 2001.
Gale EAM. Lessons from the glitazones: A story of drug development. The Lancet. 2001;357:1870-5.
Krentz AJ, Bailey C, Melander A. Thiazolidinediones for type 2 diabetes. BMJ. 2000;321:252-3.
Turner RC, Cull CA, Frighi V, Holman RR. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-12.
